Maria KręCicka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria KręCicka has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Sławomir Zmonarski
Medical University of Wrocław
1 shared publication - Wiktoria Andryszkiewicz
Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
1 shared publication - Zuzanna Cichowska
Wroclaw Medical University
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3395
SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective
People affected by diabetes mellitus (DM), chronic kidney disease (CKD), or heart failure are often prescribed sodium–glucose cotransporter-2 inhibitors (SGLT2is) as a method of treatment. These drugs favorably affect glucose metabolism, as patients taking them have lower serum glucose levels. Another promising positive impact is protection against microvascular damage, cardiovascular disease, and chronic kidney disease. Nevertheless, fungal infections, urinary tract infections, and ketoacidosis are the adverse effects that might happen during the SGLT2i treatment. Fungal infections are more common among patients treated with these medications, including vulvovaginal Candidiasis in women and balanitis or balanoposthitis in men. Given the difficulty of treating fungal infections in patients with co-occurring diseases, we recommend that ongoing supervision of patients treated with SGLT2i include prevention and early detection of fungal infections.
- 29 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3395
Open AccessSGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections—A Nephrologist’s Perspective
People affected by diabetes mellitus (DM), chronic kidney disease (CKD), or heart failure are often prescribed sodium–glucose cotransporter-2 inhibitors (SGLT2is) as a method of treatment. These drugs favorably affect glucose metabolism, as patients taking them have lower serum glucose levels. Another promising positive impact is protection against microvascular damage, cardiovascular disease, and chronic kidney disease. Nevertheless, fungal infections, urinary tract infections, and ketoacidosis are the adverse effects that might happen during the SGLT2i treatment. Fungal infections are more common among patients treated with these medications, including vulvovaginal Candidiasis in women and balanitis or balanoposthitis in men. Given the difficulty of treating fungal infections in patients with co-occurring diseases, we recommend that ongoing supervision of patients treated with SGLT2i include prevention and early detection of fungal infections.